ASLAN Pharma Granted US Orphan Drug Status for Cancer Drug

ASLAN Pharma of Singapore received US Orphan Drug Designation for ASLAN001 (varlitinib), a pan-HER inhibitor, as a treatment for cholangiocarcinoma. The disease is a rare, aggressive form of bile duct cancer that has no cure; its incidence in China is ten times that of the west. Last month, ASLAN said one cholangiocarcinoma patient in a Phase II trial of ASLAN001 experienced an 87% shrinkage of his tumor. With Orphan Drug Designation, ASLAN001 will have a longer exclusivity period in the US. More details.... Share this with colleagues: // //